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Abstract
Background: With recent developments in tissue engineering technology, various three-dimensional tissues can be
generated now. However, as the tissue thickness increases due to three-dimensionalization, it is difficult to increase
the tissue scale without introduction of blood vessels.
Main text: Many methods for vasculature induction have been reported recently. In this review, we introduced
several methods which are adjustable vascularization in three-dimensional tissues according to three steps. First,
“selection” provides potents for engineered tissues with vascularization ability. Second, “assembly technology” is
used to fabricate tissues as three-dimensional structures and simultaneously inner neo-vasculature. Third, a
“perfusion” technique is used for maturation of blood vessels in three-dimensional tissues. In “selection”, selection of
cells and materials gives the ability to promote angiogenesis in three-dimensional tissues. During the cell assembly
step, cell sheet engineering, nanofilm coating technology, and three-dimensional printing technology could be
used to produce vascularized three-dimensional tissues. Perfusion techniques to perfuse blood or cell culture
medium throughout three-dimensional tissues with a unified inlet and outlet could induce functional blood vessels
within retransplantable three-dimensional tissues. Combination of each step technology allows simulation of
perivascular microenvironments in target tissues and drive vascularization in three-dimensional tissues.
Conclusion: The biomimetic microenvironment of target tissues will induce adequate cell-cell interaction, distance,
cell morphology, and function within tissues. It could be accelerated for vascularization within three-dimensional
tissues and give us the functional tissues. Since vascularized three-dimensional tissues are highly functional, they are
expected to contribute to the development of regenerative medicine and drug safety tests for drug discovery in
the future.
Keywords: Induction vascularization, Selecting cells and material, Tissue engineering, Assemble, Perfusion,
Three-dimensional tissues
Background
Tissue engineering (TE) technologies have been progres-
sing recently. The development of these technologies
has produced dramatic effects on cell transplantation
therapy [1, 2]. Moreover, three-dimensional (3D) struc-
tures fabricated from cells express important functions
and the differentiation capacity of stem cells in vitro.
These 3D tissues will be also available as tools for safety
tests on chemical substances or for drug discovery. In-
deed, a reduction in the use of animals for laboratory ex-
periments is required globally for the drug development
process and other applications, from the perspective of
animal welfare. The use of animal-free technology to
fabricate tissues will accelerate this reduction.
As the thickness of engineered 3D tissue increases,
however, induction of inner vasculature is required in
order to supply oxygen and nutrients, including fatty
acids, and remove waste products. In typical two-
dimensional (2D) cell culture conditions, the thickness
of the cell population is approximately 20–30 μm, which
is sufficient to allow diffusion of nutrients and oxygen.
When the thickness of engineered tissues exceeds
100 μm, the oxygen and nutrients are difficult to diffuse
to the inner side of the tissue [3]. Therefore, to resolve
this thickness issue, introducing blood vessels into 3D
engineered tissues has been studied, and various meth-
odologies to achieve this have been established [4, 5].
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For example, tissues exceeding 1 mm in thickness can
be obtained in vivo when the 80-μm layered cell sheets
are multistep-transplanted with a vascular linkage be-
tween each layered cell sheet [6]. Moreover, a perfusable
system and micro-perfusable channel have recently been
developed in vitro for 3D tissue vascularization. In this
review, we will introduce the latest vessel induction
strategies according to three steps: selecting cells and
materials for vascularized 3D tissues, assembly selecting
parts as vascularized 3D shapes, and promotion of
vascularization, with perfusable culture (Fig. 1). Combin-
ation of these technologies will produce physiological
mimic microenvironment in vivo and could drive
vascularization for target engineered tissues. Such bio-
mimetic microenvironments can approach the engi-
neered tissues close to the ideal function and structure.
Selecting cells and materials for vascularization into 3D
engineered tissues
During fabrication of 3D tissues from cells, it is necessary
to induce the generation of blood vessels simultaneously.
For conditioning vascularization microenvironments, we
have to choose potent cells and materials including acti-
vating growth factor and promoting scaffold within 3D tis-
sues (Fig. 2).
Cells constructing vasculature, endothelium-
constructed endothelial cells (human umbilical vein endo-
thelial cell: HUVEC, endothelial progenitor cell: EPC, and
other kinds of endothelial cell: EC), and perivascular-
constructed cells (mesenchymal stem cell: MSC and
smooth muscle cell: SMC) could be considered as potent
cells for vascularization within tissues. Selecting these cells
is dependent on kinds of target tissue.
Simply coculturing cells is a technique to induce blood
vessels within engineering of 3D tissues. Secreting cyto-
kines and other factors, including cell adhesion factors
and extracellular matrix (ECM), from cocultured cells
induce the neo-vasculature within 3D tissues. Previously,
myocardial sheets with a vascular EC network structure
could be fabricated by cultivation with vascular ECs and
fetal left ventricle-derived cardiomyocytes [7]. The myo-
cardial cell sheet contained not only ECs and myocardial
cells but also fibroblasts and pericytes. This EC network
containing myocardial tissue was able to promote blood
circulation shortly, which guarantees the survival and
growth of 3D tissues after transplantation in vivo [8].
Actually, the tricultured scaffold with ECs, myoblasts,
and fibroblasts also induced vasculature within 3D tis-
sues in vitro [9]. In contrast, the EC network can also
observe during differentiation into hepatocytes from
endoderm-differentiated induced pluripotent stem (iPS)
cells by coculture [10] and renal tubular cells from iPS
cells [11]. These EC networks within primitive tissues
are probably similar to the primary vascular plexus dur-
ing the embryonic period, which is associated with the
supply of blood flow promptly into immature tissues
during development. Thus, EC networks are considered
as one better indicator of selecting cells for vascularized
3D tissues.
The EC network structure could be also induced by
coculture with dermal fibroblasts, skeletal myoblasts,
adipose-derived MSCs (ADMSCs), and bone marrow-
derived MSCs (BMMSCs) [12–14]. In particular, MSCs
could differentiate into vascular ECs [15], and pericytes
could be also considered as adipose-derived MSCs [16].
Thus, MSCs have probably potents for promotion angio-
genesis within the engineered 3D tissue. Notably, after
transplantation, MSC-containing 3D tissues showed
greater regeneration than that without MSCs by indu-
cing macrophage infiltration [17]. Macrophage infiltra-
tion due to inflammation alters the EC network
structure in vitro and promotes angiogenesis in vivo
[18]. MSCs also exhibit immunomodulation after bone
marrow transplantation [19]. This ability of MSCs to
Fig. 1 Vascularized 3D tissue fabrication strategy for creating biomimetic microenvironments. The figure shows a flow chart of vessel induction
strategies according to three steps: selecting cells and materials for vascularized ability within 3D tissues, assembly technology as the method of
3D fabrication which control distribution and promotion of vascularization, and perfusable culture for functional vascular maturation
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affect inflammation may accelerate induction of vascu-
larized 3D tissues in vivo.
Growth factor is also important for vascularization of
3D tissues. Culture medium containing growth factor is
well known to induce vascularization in 3D tissues [20].
However, angiogenesis-promoting factors, vascular
endothelial growth factor (VEGF), basic fibroblast
growth factor (bFGF), hepatocyte growth factor (HGF),
platelet-derived growth factor-BB (PDGF-BB), and
angiopoietin-1 have common issues, quickly degradation
and diffusion. To overcome these issues, we immobilized
them with scaffolds [21] or co-cultured with VEGF
transgenic cells [22]. It is also able to administrate sus-
tained growth factors for local interested sites and cause
gradients of growth factors [23]. It was reported that mi-
crovasculature is induced at the transplant position be-
fore transplantation via administration of a sustained-
release VEGF or bFGF, to enhance vascularization of im-
planted 3D tissues [24]. Thus, the controlled release
growth factors can be useful for vascularization within
engineered 3D tissues.
Selecting scaffold materials (e.g., synthetic polymers and
natural polymers) is also important for vascularization of
3D tissues [25]. Co-polymer of poly lactic acid (PLA) and
poly glycolic acid (PGA) and poly-(L-lactide) (PLLA) and
poly –(lactic-co-glycolic) acid (PLGA) are well known as
synthetic biodegradable polymers for 3D tissue fabrication.
Natural polymers, collagen, fibronectin, and hyaluronic
acid are also well utilized for vascularization of 3D tissues.
Especially, extracellular matrix component could affect
ECs adhesion and proliferation. These polymers could
combine with each other for 3D tissue fabrication. In prior
studies, well-vascularized 3D skeletal muscle tissues were
fabricated in vivo with PLLA/PLGA scaffolds [26]. The
EC network structures have been obtained within tri-cell
cultured 3D tissues by adding fibrin to PLLA/PLGA scaffold
during cultivation [27]. Moreover, mechanical characters
(e.g., porous size and stiffness) of scaffold affected for
vascularization ability within 3D tissues. The vascularization
within the 3D tissue is probably controlled scaffold size,
mechanical or chemical character optimization of the co-
polymer biodegradation time [28]. Good selecting materials
as scaffolds will mediate for vascularized 3D tissues.
Summarizing, suitable selective cells and materials are
an important step for vascularization ability, EC-
network formation, and vascular density inner 3D engi-
neered tissues.
Assembly of cells into vascularized 3D engineered tissues:
cell manipulation and scaffold shaping
Following selection step, cells and materials have to
be arranged artificially or efficiently self-organization.
Therefore, the assembly of cells and materials is an-
other key point for fabrication of 3D tissues with vas-
culature (Fig. 3).
Recently, the thin coating of proteins on individual cell
surfaces has been reported to facilitate the fabrication of
3D tissues without a scaffold in vitro [29]. The coated
Fig. 2 Selection of cells and materials. The figure shows several candidates of potent cells and materials including activating growth factor and
promoting scaffold within 3D tissues for conditioning vascularization microenvironments
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cells are cultured on a porous permeable membrane.
After adhesion of the basic layer, the next layer of cells is
cultured; this process is repeated to fabricate a 3D struc-
ture. Using this process, researchers have succeeded in
constructing 3D tissues having an EC network structure
by improving the cell-coating steps. Because nanofilm
coating technology can be used to fabricate 3D tissues
layer by layer, it cannot increase the thickness dynamic-
ally. In cell sheet technology, the thickness of a 3D tissue
can be increased in units of several numbers of cell
layers. Cell sheet technology uses cell culture dishes
coated with the thermoresponsive polymer poly(N-iso-
propylacrylamide) (PIPAAM) with nanometer-level
thickness [30]. These dishes allow cultured cells to be
detached from the culture surface as cell sheets at a
temperature of less than 32 °C. Simple ordinal cell cul-
ture methods with temperature-responsive culture
dishes can be used to engineer 2D cell sheets under ad-
equate temperature conditions. Preserved adhesive fac-
tors in fabricated 2D cell sheets are advantageous for re-
adhesion during layering through adhesive factors re-
leased by the cells using the gelatin-gel stamp technique
[31]. The stamp techniques allow several number of cell
sheets layering for an hour. Fabricated 3D tissues with
layered cell sheets can also be manipulated by highly in-
telligent tools [32].
As described above, prompt blood flow can be
achieved in engineering of 3D tissues with cell sheet
technology after transplantation because of preserved
EC network during the fabrication of 3D tissues [7]. The
network can be established as immature vessels in
transplanted 3D tissues within 24 h after transplantation.
Even when only coculturing ECs and mesenchymal cells
within Matrigel, at least 3 days are required to supply
blood flow [33]. Thus, cell sheet technology can create
dense 3D tissues with vascularization in vivo by exploit-
ing the functions of the cells. In vitro EC networks and
in vivo blood perfusion are achieved more quickly
through cell sheet technology than scaffold or nanofilm
coating technology (Table 1).
Additionally, vessels within tissues align and
organize naturally into appropriate shapes and struc-
tures in vivo. Patterning techniques have been actively
studied to create 2D shapes by micropatterning cell
adhesive areas or nonadhesive areas on the surfaces
of cell culture materials [34]. Microprinting of adhe-
sive protein on the surface has also been achieved
with polydimethylsiloxane (PDMS) micropatterning
technology [35]. For lining cells in a specific direc-
tion, culture dishes having microgroove grids have
also been studied [36]. These 2D patterning tech-
niques could be combined with cell sheet layering
methods to create precise 3D structures. However,
patterning at the micrometer or nanometer level, i.e.,
smaller than the size of a cell (less than approxi-
mately 10 μm), tends to make cells disorganized
within 3D cell-dense tissues. Moreover, 2D patterning
structures can be modified easily by the surrounding
cells. Compared with micropatterning technology, 3D
bioprinting of cell-shaping scale is larger than micro-
patterning. Although a delicate pattern cannot be cre-
ated, techniques that can control the amount of
Fig. 3 Assembly technology. The figure shows representative assembly technology for fabrication of 3D tissues with vasculature
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blood vessels arranged in a 3D tissue are expected to
be suitable for intentional blood vessel guidance into
3D tissues [37].
Native patterning and ECM could be used for tissue
engineering with decellularized scaffold technique.
Decellularized tissues are then recellularized with vascu-
lar ECs and perfused in vitro and in vivo. The kidneys of
animals were decellularized and reseeded with human
target cells [38]. Since the cell engraftment and infiltra-
tion of recellularization are affected by the decellulariza-
tion protocol [39], further studies are needed to allow
application of this technology.
These assembly methods have benefits and disadvan-
tages (Table 2), and the appropriate method must be
chosen based on the target tissue characteristics and ap-
plications. Because assembly technology will develop
really day by day, we have to obtain information and ar-
range them adequately for target tissues.
Perfusion for maturation of vasculature within 3D tissues:
fabrication perfusable basement for perfusion stimulation
within vasculature within 3D tissues
Blood vessels function to transport blood throughout tis-
sues and organs. During the embryonic stage, after
vascularization, redundant vessels are remodeled [40].
Thus, if blood perfusion does not occur through vessel
or EC networks, they should be removed as redundant
vasculature. Researchers have used traditional ap-
proaches to perfuse 3D tissues, including transplantation
into animals to exploit biological circulation. In the se-
lection of transplantation position, highly vascular sites,
e.g., the kidney capsule, are usually chosen. However,
engineered tissues have to be re-transplanted for thera-
peutic application. Accordingly, in the field of plastic
surgery, the arteriovenous (AV) loop has been used to
make a flap for promotion of vascularized 3D fabricated
tissues [41, 42], allowing retransplantation into another
site for maturation of 3D tissues by vascular anasto-
mosis. Recently, vascular beds made from rat femoral
tissues were perfused ex vivo, and 3D myocardial tissue
was developed using cell sheet technology [43] (Fig. 4a).
In recent studies, microchannels within biodegradable
scaffolds or ECM gel, such as collagen or fibrin, have
been fabricated for perfusion into the channel. These
microchannels have been employed in “body-on-a-chip”
technology with PDMS microprocessing [44]. In our la-
boratory, a collagen gel microperfusable basement was
vascularized by cell sheet technology [45]. Furthermore,
microperfusable tubes were endothelialized with cells
derived from cell sheets. Compared with the natural cir-
culation system, these perfusable gel structures have no
paracrine effects. By cocultivation with MSC inner scaf-
folds or ECM gel, it becomes possible to establish an ef-
fective perfusable basement for 3D tissue containing
blood vessels without using animals. Microchannel fabri-
cated by 3D printer with water-soluble polymer (poly
vinyl alcohol: PVA) was also used as sacrificed template
technique with embedding gelatin gel. The channel scale
Table 1 Comparison of EC-network assembly technologies. This table indicates the comparison of the period of EC network forma-
tion and connection to host blood circulation after transplantation among three assembly technologies, scaffold, and nanofilm coat-
ing and cell sheet technology
Technology EC EC network cultivation
periods
Cocultured cells Ratio of
EC





HUVEC 3~7 days Fibroblast Skeletal muscle
cells
10~80% Done (day 10) [9, 26]
Nano film
coating
HUVEC 3 day Fibroblast, MSC, iPS,
myocardial cells
9% non [29]
Cell sheet Rat EC,
HUVEC,
1 3 days Fibroblast, SMC, myocardial
cell
8~10% Done (within 24 h) [7, 8, 12]
Comparison of EC-network assembly technologies
Table 2 Assembly technology. The table shows several advantages and disadvantages of assembly technologies




Self-organization within scaffold or
recellularization native vasculature ECM within
decellularized tissues
Controlled selforganization with
scaffold characters or native ECM
and shape
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was more than 1 mm [46]. Perfusable vasculature under
100-μm diameter was also microfabricated by EC encap-
sulation with polymer by hydrodynamic shaping and
photopolymerization. After embedded matrix, the
microfabricated vessel could make branches from them
[47]. More natural complex vasculature were tried to
fabricate with perfusion poly caprolactone (PLC) cast
into natural kidney vasculature. They digested kidney
tissues without PLC cast and coated with collagen
matrix. Finally, the PLC cast was removed as sacrificed
template and remained complex structure of hollow col-
lagen scaffolds (Fig. 4b animal material-applicated sacri-
ficial template). They could be used as perfusable
microvasculature basement for engineered 3D tissues
[48]. Perfusion stimulation causes biomechanics for mat-
uration of vasculature within 3D tissues. However, perfu-
sion medium has to be conditioned well. Especially,
oxygen delivery carrier replaced to erythrocytes was im-
portant to maintain and maturate tissues [49]. Since
these methodologies have also advantages and disadvan-
tages (Table 3), we have to choose and combine these
technologies according to suitable microenvironment for
vascularization of target 3D tissues. In fact, vascularized
cardiac cell tissues could be obtained in vivo and in vitro
with perfusable cultivation [43, 45]. Moreover, 3D vascu-
larized engineered tissues were reported to be obtained
Fig. 4 Perfusable culture technology. The figure illustrates representative perfusion culture technology for fabrication of 3D tissues
with vasculature
Table 3 Perfusion culture technology. The table shows several advantages and disadvantages of perfusion culture technologies





Without high technique and prompt
vascularization
The size of transplantation tissues have
limitation
[7, 8]
AV-loop flap Prompt vascularization and retransplantation
with vascular anastomosis





Native vasculature can apply Difficulty of maintaining animal




Animal-free experiments Necessity of promotion vascularization
ability
[45]
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with perfusion culture for 2 weeks in vitro [50, 51].
Thus, multistep vascularized tissue engineering is one of
actualizing strategies for fabrication of functional vascu-
larized 3D tissues.
Conclusion
In the fields of regenerative medicine and drug discov-
ery, vascularized 3D tissues are needed for continued
progress and the development of effective treatments.
Key points for inducing vasculature within 3D tissues
are selection of cells and materials, assembly methods,
and perfusion techniques. In the past few decades, many
technologies have been produced for generation of vas-
cularized 3D tissues. Because there are numerous op-
tions for engineering 3D tissues, it is necessary to make
an appropriate selection considering the specific target
tissue. At the point to choose them, it is essential to
understand suitable or native microenvironment for the
target-tissue situation in vivo. The biomimetic micro-
environment of target tissues will induce adequate cell-
cell interaction, distance, cell morphology, and function
within tissues. For fabrication of the microenvironment,
multistep combination technologies might be a candi-
date of an actual strategy for vascularization within 3D
tissues. It could progress for fabrication of vascularized
3D tissues and give us the generation functional tissues.
We hope that these artificial tissue or organs will facili-
tate the development of effective treatment strategies for
patients with intractable diseases in the future.
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